{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,18]],"date-time":"2026-04-18T06:48:10Z","timestamp":1776494890892,"version":"3.51.2"},"reference-count":22,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2018,3,19]],"date-time":"2018-03-19T00:00:00Z","timestamp":1521417600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["PharmacoEconomics"],"published-print":{"date-parts":[[2018,5]]},"DOI":"10.1007\/s40273-018-0643-4","type":"journal-article","created":{"date-parts":[[2018,3,19]],"date-time":"2018-03-19T12:22:54Z","timestamp":1521462174000},"page":"625-636","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Cost-Effectiveness Analysis of Lesinurad\/Allopurinol Versus Febuxostat for the Management of Gout\/Hyperuricemia in Italy"],"prefix":"10.1007","volume":"36","author":[{"given":"M.","family":"Ruggeri","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1098-2648","authenticated-orcid":false,"given":"M.","family":"Basile","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.","family":"Drago","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"F. R.","family":"Rolli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Cicchetti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2018,3,19]]},"reference":[{"issue":"10","key":"643_CR1","doi-asserted-by":"publisher","first-page":"1312","DOI":"10.1136\/ard.2006.055269","volume":"65","author":"W Zhang","year":"2006","unstructured":"Zhang W, Doherty M, Bardin T, Pascual E, Barskova V, Conaghan P, et al. EULAR evidence based recommendations for gout. Part II: management. Report of a task force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT). Ann Rheum Dis. 2006;65(10):1312\u201324.","journal-title":"Ann Rheum Dis"},{"issue":"6","key":"643_CR2","first-page":"1501","volume":"27","author":"KC Lin","year":"2000","unstructured":"Lin KC, Lin HY, Chou P. The interaction between uric acid level and other risk factors on the development of gout among asymptomatic hyperuricemic men in a prospective study. J Rheumatol. 2000;27(6):1501\u20135.","journal-title":"J Rheumatol"},{"issue":"6","key":"643_CR3","first-page":"819","volume":"23","author":"F Salaffi","year":"2004","unstructured":"Salaffi F, De Angelis R, Grassi W. Prevalence of musculoskeletal conditions in an Italian population sample: results of a regional community-based study. I. The MAPPING study. Clin Exp Rheumatol. 2004;23(6):819\u201328.","journal-title":"Clin Exp Rheumatol"},{"issue":"1","key":"643_CR4","doi-asserted-by":"publisher","first-page":"S2","DOI":"10.1186\/ar1907","volume":"8","author":"KG Saag","year":"2006","unstructured":"Saag KG, Choi H. Epidemiology, risk factors, and lifestyle modifications for gout. Arthritis Res Ther. 2006;8(1):S2.","journal-title":"Arthritis Res Ther"},{"issue":"5S","key":"643_CR5","doi-asserted-by":"publisher","first-page":"S55","DOI":"10.1097\/RHU.0b013e3181896921","volume":"14","author":"LX Chen","year":"2008","unstructured":"Chen LX, Schumacher HR. Gout: an evidence-based review. J Clin Rheumatol. 2008;14(5S):S55\u201362.","journal-title":"J Clin Rheumatol."},{"issue":"12","key":"643_CR6","first-page":"2429","volume":"31","author":"GC Borstad","year":"2004","unstructured":"Borstad GC, Bryant LR, Abel MP, Scroggie DA, Harris MD, Alloway JA. Colchicine for prophylaxis of acute flares when initiating allopurinol for chronic gouty arthritis. J Rheumatol. 2004;31(12):2429\u201332.","journal-title":"J Rheumatol"},{"issue":"23","key":"643_CR7","doi-asserted-by":"publisher","first-page":"2450","DOI":"10.1056\/NEJMoa050373","volume":"353","author":"MA Becker","year":"2005","unstructured":"Becker MA, Schumacher HR Jr, Wortmann RL, MacDonald PA, Eustace D, Palo WA, et al. Febuxostat compared with allopurinol in patients with hyperuricemia and gout. N Engl J Med. 2005;353(23):2450\u201361.","journal-title":"N Engl J Med"},{"key":"643_CR8","unstructured":"Food and Drug Administration. http:\/\/www.fda.gov\/NewsEvents\/Newsroom\/PressAnnouncements\/ucm478791.htm . Accessed 27 Sept 2017."},{"issue":"5","key":"643_CR9","doi-asserted-by":"publisher","first-page":"815","DOI":"10.1007\/s11136-008-9355-0","volume":"17","author":"D Khanna","year":"2008","unstructured":"Khanna D, Ahmed M, Yontz D, Ginsburg SS, Park GS, Leonard A, et al. The disutility of chronic gout. Qual Life Res. 2008;17(5):815\u201322.","journal-title":"Qual Life Res"},{"key":"643_CR10","unstructured":"Istituto Nazionale di Statistica. http:\/\/www.istat.it\/it . Accessed 19 May 2017."},{"issue":"2","key":"643_CR11","first-page":"165","volume":"21","author":"PK Gandhi","year":"2015","unstructured":"Gandhi PK, Gentry WM, Ma Q, Bottorff MB. Cost-effectiveness analysis of allopurinol versus febuxostat in chronic gout patients: a US payer perspective. J Manag Care Spec Pharm. 2015;21(2):165\u201375.","journal-title":"J Manag Care Spec Pharm"},{"issue":"4","key":"643_CR12","doi-asserted-by":"publisher","first-page":"500","DOI":"10.1177\/0272989X09340585","volume":"29","author":"JJ Barendregt","year":"2009","unstructured":"Barendregt JJ. The half-cycle correction: banish rather than explain it. Med Decis Mak. 2009;29(4):500\u20132.","journal-title":"Med Decis Mak"},{"issue":"4","key":"643_CR13","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1007\/s40258-017-0311-4","volume":"15","author":"M Ruggeri","year":"2017","unstructured":"Ruggeri M, Basile M, Coretti S, Drago C, Cicchetti A. Economic analysis and budget impact of tenofovir and entecavir in the first-line treatment of hepatitis B virus in Italy. Appl Health Econ Health Policy. 2017;15(4):479\u201390.","journal-title":"Appl Health Econ Health Policy"},{"issue":"Suppl 4","key":"643_CR14","first-page":"523","volume":"50","author":"A Snow-Lampart","year":"2009","unstructured":"Snow-Lampart A, Chappell BJ, Curtis M, et al. HBeAg\u2009+\u2009and HBeAg hepatitis B patients treated with tenofovir df showed no relationship between virologic breakthrough and emergence of genotypic changes in HBV polymerase. Hepatology. 2009;50(Suppl 4):523.","journal-title":"Hepatology"},{"issue":"5","key":"643_CR15","doi-asserted-by":"publisher","first-page":"811","DOI":"10.1136\/annrheumdis-2016-209213","volume":"76","author":"T Bardin","year":"2017","unstructured":"Bardin T, Keenan RT, Khanna PP, Kopicko J, Fung M, Bhakta N, et al. Lesinurad in combination with allopurinol: a randomised, double-blind, placebo-controlled study in patients with gout with inadequate response to standard of care (the multinational CLEAR 2 study). Ann Rheum Dis. 2017;76(5):811\u201320.","journal-title":"Ann Rheum Dis"},{"issue":"Suppl 2","key":"643_CR16","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1136\/annrheumdis-2015-eular.2182","volume":"74","author":"N Dalbeth","year":"2015","unstructured":"Dalbeth N, Jones G, Terkeltaub R, Khanna D, Kopicko J, Bhakta N, et al. SAT0329 Lesinurad, a novel selective uric acid reabsorption inhibitor, in combination with febuxostat, in patients with tophaceous gout: the CRYSTAL phase III clinical trial. Ann Rheum Dis. 2015;74(Suppl 2):778.","journal-title":"Ann Rheum Dis"},{"key":"643_CR17","unstructured":"National Institute for Health Care Excellence. Single technology assessment\u2014lesinurad for treating chronic hyperuricaemia in people with gout (2016). https:\/\/www.nice.org.uk\/guidance\/ta506\/documents\/committee-papers ."},{"key":"643_CR18","unstructured":"Ministero della Salute. Nomenclatore tariffario dell\u2019assistenza specialistica ambulatoriale. http:\/\/www.salute.gov.it\/portale\/temi\/p2_6.jsp?id=1767&area=programmazioneSanitariaLea&menu=lea . Accessed Apr 2016."},{"key":"643_CR19","unstructured":"AIFA \u2013 Agenzia Italiana del Farmaco. Prontuario farmaceutico Nazionale. http:\/\/www.agenziafarmaco.gov.it\/it\/content\/prontuario-farmaceutico-nazionale . Accessed Apr 2016."},{"key":"643_CR20","volume-title":"Global sensitivity analysis: the primer","author":"A Saltelli","year":"2008","unstructured":"Saltelli A, Ratto M, Andres T, Campolongo F, Cariboni J, Gatelli D, et al. Global sensitivity analysis: the primer. Chichester: John Wiley & Sons; 2008."},{"key":"643_CR21","doi-asserted-by":"crossref","DOI":"10.1093\/oso\/9780198526629.001.0001","volume-title":"Decision modelling for health economic evaluation. Handbooks in health economic evaluation","author":"AH Briggs","year":"2006","unstructured":"Briggs AH, Claxton K, Sculpher MJ. Decision modelling for health economic evaluation. Handbooks in health economic evaluation. Oxford: Oxford University Press; 2006."},{"issue":"2","key":"643_CR22","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1177\/0272989X8500500205","volume":"5","author":"P Doubilet","year":"1984","unstructured":"Doubilet P, Begg CB, Weinstein MC, Braun P, McNeil BJ. Probabilistic sensitivity analysis using Monte Carlo simulation. A practical approach. Med Decis Mak. 1984;5(2):157\u201377.","journal-title":"Med Decis Mak"}],"container-title":["PharmacoEconomics"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40273-018-0643-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40273-018-0643-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40273-018-0643-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,2]],"date-time":"2025-07-02T21:39:06Z","timestamp":1751492346000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40273-018-0643-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,3,19]]},"references-count":22,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2018,5]]}},"alternative-id":["643"],"URL":"https:\/\/doi.org\/10.1007\/s40273-018-0643-4","relation":{},"ISSN":["1170-7690","1179-2027"],"issn-type":[{"value":"1170-7690","type":"print"},{"value":"1179-2027","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,3,19]]},"assertion":[{"value":"19 March 2018","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"This study was funded by Grunenthal Italia. The views expressed here are those of the authors and not necessarily those of the funders.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"None of the authors (Dr. Ruggeri, Dr. Basile, Dr. Drago, and Prof. Cicchetti) has any potential conflict of interest related to this study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}